chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: LITTLE PAIN AT INJECTION SHOT; This spontaneous report received from a consumer concerned a 64 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: non smoker, and non alcoholic, and other pre-existing medical conditions included: Patient had no known drug allergies and did not had any drug abuse or illicit drug use. The patient was previously treated with tetanus vaccine. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 07-APR-2021, the patient experienced little pain at injection shot. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from little pain at injection shot. This report was non-serious. This case, from the same reporter is linked to 20210900297, and 20210900823.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Nausea, Pyrexia
Clinical narrative: CHILLS; NAUSEA; FEVER; HEADACHE; This spontaneous report received from a parent concerned a 25 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced chills, nausea, fever, and headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the nausea, fever, headache and chills was not reported. This report was non-serious.
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea
Clinical narrative: feels a little nausea; headaches; A spontaneous report was received from a healthcare professional concerning a 83-years-old  patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events headaches, feels a little nausea.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 4 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 013M20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 4 Feb 2021, the patient experienced the event(s) headaches,On 5 Feb 2021, the patient experienced the event(s) feels a little nausea.  Treatment details included She has been taking Tylenol for the headaches, but it doesn't seem to be doing too much..  Action taken with mRNA-1273 in response to the events was not reported.  On 6 Feb 2021 the outcome of event(s), feels a little nausea was resolved. The outcome of event(s), headaches was unknown.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature decreased, Nausea, Weight increased
Clinical narrative: gained 11 lbs with snacking; 20 minutes after shot felt nauseous/Nausea continues off and on all Day/More nausea than relief/feels nauseous in between breakfast and lunch; coolness over the body; This spontaneous case was reported by a consumer and describes the occurrence of BODY TEMPERATURE DECREASED (coolness over the body), WEIGHT INCREASED (gained 11 lbs with snacking) and NAUSEA (20 minutes after shot felt nauseous/Nausea continues off and on all Day/More nausea than relief/feels nauseous in between breakfast and lunch) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013L20A and 012M20A) for COVID-19 vaccination.     The patient's past medical history included Acid reflux (oesophageal). Concurrent medical conditions included Drug allergy (Aspirin.), Penicillin allergy and Allergy to antibiotic (Erythromycin). Concomitant products included ESOMEPRAZOLE SODIUM (NEXIUM [ESOMEPRAZOLE SODIUM]) for Acid reflux (oesophageal), LEVOCETIRIZINE DIHYDROCHLORIDE (LEVOCETRIZINE HYDROCHLORIDE) for Blood pressure, PANTOPRAZOLE and LISINOPRIL for an unknown indication.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced BODY TEMPERATURE DECREASED (coolness over the body). On 12-Feb-2021, the patient experienced NAUSEA (20 minutes after shot felt nauseous/Nausea continues off and on all Day/More nausea than relief/feels nauseous in between breakfast and lunch). On an unknown date, the patient experienced WEIGHT INCREASED (gained 11 lbs with snacking). The patient was treated with CALCIUM CARBONATE (MAALOX [CALCIUM CARBONATE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, BODY TEMPERATURE DECREASED (coolness over the body) and WEIGHT INCREASED (gained 11 lbs with snacking) outcome was unknown and NAUSEA (20 minutes after shot felt nauseous/Nausea continues off and on all Day/More nausea than relief/feels nauseous in between breakfast and lunch) had not resolved.            This case was linked to MOD-2021-232193 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 21-Apr-2021: Follow up information received on 21-Apr-2021 contains information of  event. The outcome of the event (Nausea )is unknown has been updated. On 23-Jun-2021: Follow up information received on 23-jun-2021 contains significant information. Patient height and body weight and race has been updated. Patient medical history include Drug Allergy to Aspirin and penicillin and erythromycin has been updated. Event (Nausea) with outcome not recovered has been updated. On 13-Aug-2021: Follow up received and added new events.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Therapeutic response unexpected
Clinical narrative: Pruritus has resolved since receiving both doses; Received second dose 38 days after first dose; This spontaneous case was reported by a dentist and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Pruritus has resolved since receiving both doses) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 38 days after first dose) in an 85-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 026L20A) for COVID-19 vaccination.     The patient's past medical history included Lymphadenectomy (No lymph nodes in right armpit due to removal of melanoma 50 years ago) and Thyroidectomy (Removed thyroid). Concurrent medical conditions included Pruritus since 16-Nov-2019, Allergy to antibiotic (Cipro), Drug allergy and Drug allergy. Concomitant products included MULTIVITAMIN [VITAMINS NOS], ESOMEPRAZOLE MAGNESIUM (NEXIUM [ESOMEPRAZOLE MAGNESIUM]), FAMOTIDINE (PEPCID [FAMOTIDINE]), LEVOTHYROXINE SODIUM (SYNTHROID) and ASCORBIC ACID, CALCIUM, MINERALS NOS, RETINOL, TOCOPHERYL ACETATE, VITAMIN B NOS, VITAMINS NOS, ZINC (CENTRUM SILVER [ASCORBIC ACID;CALCIUM;MINERALS NOS;RETINOL;TOCOPHERYL ACETATE;VITAMIN B NOS;VITAMINS NOS;ZINC]) for an unknown indication.   On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 38 days after first dose). On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Pruritus has resolved since receiving both doses). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Pruritus has resolved since receiving both doses) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 38 days after first dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Aug-2021: Follow-up information received captured allergies reporter details and patient demographic details and patient reported not experiencing adverse events.
Sex: U
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: rashes on different parts of the body; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of RASH (rashes on different parts of the body) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RASH (rashes on different parts of the body). The patient was treated with BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE (CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE) (topical) on 16-Mar-2021 for Adverse event, at an unspecified dose and frequency and BETAMETHASONE DIPROPIONATE (AUGMENTED BETAMETHASONE DIPROPIONATE) (topical) for Adverse event, at a dose of 0.05 %. At the time of the report, RASH (rashes on different parts of the body) outcome was unknown.            Concomitant medications were  not provided.  The patient's dermatologist  conducted biopsy but result was  pending.   Most recent FOLLOW-UP information incorporated above includes: On 23-Aug-2021: Non significant follow up: Contact information verified
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood pressure increased, Blood pressure measurement, Chills, Fatigue
Clinical narrative: She does not want to do anything; extreme fatigue / She is still tired; two months later her joints hurts/sore joints; Vomiting; Nausea; A couple of days later, her body ached/ two months later she still has body aches; Raised blood pressure; she had fevers; Chills; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (She does not want to do anything), BLOOD PRESSURE INCREASED (Raised blood pressure), PYREXIA (she had fevers), CHILLS (Chills) and MYALGIA (A couple of days later, her body ached/ two months later she still has body aches) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022B21A and 031B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (sulpha), Penicillin allergy, Drug allergy (Vicodin allergy) and Eczema since 1995. Concomitant products included BIOTIN for an unknown indication.   On 13-Apr-2021 at 1:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021 at 1:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-May-2021, the patient experienced BLOOD PRESSURE INCREASED (Raised blood pressure), PYREXIA (she had fevers) and CHILLS (Chills). On 12-May-2021, the patient experienced MYALGIA (A couple of days later, her body ached/ two months later she still has body aches), VOMITING (Vomiting) and NAUSEA (Nausea). 12-May-2021, the patient experienced ARTHRALGIA (two months later her joints hurts/sore joints). On 14-May-2021, the patient experienced FATIGUE (extreme fatigue / She is still tired). On 19-Jul-2021, the patient experienced LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (She does not want to do anything). The patient was treated with IBUPROFEN SODIUM (IBUPROFEN [IBUPROFEN SODIUM]) for Fever, at an unspecified dose and frequency. On 12-May-2021, BLOOD PRESSURE INCREASED (Raised blood pressure), PYREXIA (she had fevers), VOMITING (Vomiting) and NAUSEA (Nausea) had resolved. At the time of the report, LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (She does not want to do anything) outcome was unknown, CHILLS (Chills) had resolved and MYALGIA (A couple of days later, her body ached/ two months later she still has body aches), FATIGUE (extreme fatigue / She is still tired) and ARTHRALGIA (two months later her joints hurts/sore joints) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-May-2021, Blood pressure measurement: high (High) High.         This case was linked to MOD-2021-261744 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Aug-2021: Added Patient demographics, medical history, lab data, vaccine facility, concomitant medications, treatment medication, events and event outcome updated.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Loss of personal independence in daily activities, Myalgia, Nausea, Pyrexia, Vomiting
Clinical narrative: She does not want to do anything; extreme fatigue / She is still tired; two months later her joints hurts/sore joints; Vomiting; Nausea; A couple of days later, her body ached/ two months later she still has body aches; Raised blood pressure; she had fevers; Chills; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (She does not want to do anything), BLOOD PRESSURE INCREASED (Raised blood pressure), PYREXIA (she had fevers), CHILLS (Chills) and MYALGIA (A couple of days later, her body ached/ two months later she still has body aches) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022B21A and 031B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (sulpha), Penicillin allergy, Drug allergy (Vicodin allergy) and Eczema since 1995. Concomitant products included BIOTIN for an unknown indication.   On 13-Apr-2021 at 1:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021 at 1:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-May-2021, the patient experienced BLOOD PRESSURE INCREASED (Raised blood pressure), PYREXIA (she had fevers) and CHILLS (Chills). On 12-May-2021, the patient experienced MYALGIA (A couple of days later, her body ached/ two months later she still has body aches), VOMITING (Vomiting) and NAUSEA (Nausea). 12-May-2021, the patient experienced ARTHRALGIA (two months later her joints hurts/sore joints). On 14-May-2021, the patient experienced FATIGUE (extreme fatigue / She is still tired). On 19-Jul-2021, the patient experienced LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (She does not want to do anything). The patient was treated with IBUPROFEN SODIUM (IBUPROFEN [IBUPROFEN SODIUM]) for Fever, at an unspecified dose and frequency. On 12-May-2021, BLOOD PRESSURE INCREASED (Raised blood pressure), PYREXIA (she had fevers), VOMITING (Vomiting) and NAUSEA (Nausea) had resolved. At the time of the report, LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (She does not want to do anything) outcome was unknown, CHILLS (Chills) had resolved and MYALGIA (A couple of days later, her body ached/ two months later she still has body aches), FATIGUE (extreme fatigue / She is still tired) and ARTHRALGIA (two months later her joints hurts/sore joints) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-May-2021, Blood pressure measurement: high (High) High.         This case was linked to MOD-2021-261744 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Aug-2021: Added Patient demographics, medical history, lab data, vaccine facility, concomitant medications, treatment medication, events and event outcome updated.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Tired; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Tired) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     No Medical History information was reported.  Concomitant products included VITAMIN D [VITAMIN D NOS], LEVOTHYROXINE from 01-Jan-2005 to an unknown date, LISINOPRIL from 01-Jan-2005 to an unknown date and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 29-Mar-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Tired). At the time of the report, FATIGUE (Tired) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Treatment information was not provided by the reporter.   This case was linked to MOD-2021-264013, MOD-2021-263966 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 15-Aug-2021: Patient demographics added and additional concomitant medication multivitamin was added. On 17-Aug-2021: Follow-Up included no new information.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Insomnia, Myalgia, Pyrexia
Clinical narrative: Fever; Chills; Severe Fatigue; Fever; Chills; Severe Fatigue; Could not sleep; Muscle  ache; Chills; Low grade fever; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of INSOMNIA (Could not sleep), MYALGIA (Muscle  ache), the first episode of CHILLS (Chills), PYREXIA (Low grade fever) and FATIGUE (Fatigue) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027L20A and 025J20-21) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Medical history was not provided by reporter.  Concomitant products included TRAZODONE and SERTRALINE for an unknown indication.   On 05-Jan-2021 at 12:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021 at 12:30 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Mar-2021, the patient experienced MYALGIA (Muscle  ache), the first episode of CHILLS (Chills), PYREXIA (Low grade fever) and FATIGUE (Fatigue). On 09-May-2021, the patient experienced INSOMNIA (Could not sleep). On 09-May-2021 at 12:00 PM, the patient experienced the first episode of PYREXIA (Fever), the second episode of CHILLS (Chills) and the first episode of FATIGUE (Severe Fatigue). On 19-Jul-2021, the patient experienced the second episode of PYREXIA (Fever), the third episode of CHILLS (Chills) and the second episode of FATIGUE (Severe Fatigue). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) for Adverse event, at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) for Fever, at an unspecified dose and frequency. On 24-Mar-2021, PYREXIA (Low grade fever) and FATIGUE (Fatigue) had resolved. In May 2021, INSOMNIA (Could not sleep) had resolved. On 20-Jul-2021, last episode of PYREXIA (Fever), the last episode of CHILLS (Chills) and the last episode of FATIGUE (Severe Fatigue) had resolved. At the time of the report, MYALGIA (Muscle  ache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) Negative.         Most recent FOLLOW-UP information incorporated above includes: On 18-Aug-2021: Added Patients demographic includes patients height, weight, Ethnicity, Treatment medication, event insomnia and Outcome updated for events from Unknown to recovered / resolved and narrative was update accordingly.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Miliaria, Pain, Rash
Clinical narrative: stinging in his feet and hands; heated by moving too fast or walking to fast; rash on his neck, his upper chest,and both arms.; Greater than 35 days between Covid-19 doses; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (stinging in his feet and hands), MILIARIA (heated by moving too fast or walking to fast), RASH (rash on his neck, his upper chest,and both arms.) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between Covid-19 doses) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN (stinging in his feet and hands), MILIARIA (heated by moving too fast or walking to fast), RASH (rash on his neck, his upper chest,and both arms.) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between Covid-19 doses). At the time of the report, PAIN (stinging in his feet and hands), MILIARIA (heated by moving too fast or walking to fast) and RASH (rash on his neck, his upper chest,and both arms.) outcome was unknown and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between Covid-19 doses) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment and concomitant product information was not provided.  The dermatologist told him to get an anti-itch cream which helps to cool him. His dermatologist also said there was nothing in the Moderna vaccine that cause an allergic reaction nor does not have allergies. However, his immune system is overworked, and making too many antibodies. Patient restated the dermatologist told him the proteins in his body was causing him to develop antibodies. Patient stated he does not plan to obtain the 2nd vaccine.   This case was linked to MOD-2021-270627, MOD-2021-229942 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: First dose information was updated, new events were  added.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Pruritus, Vaccination site pain
Clinical narrative: Intermittent itching palms,bilateral itching palms,intermittent itching knuckles; Pain at the injection site; Achy knee issue; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Intermittent itching palms,bilateral itching palms,intermittent itching knuckles), VACCINATION SITE PAIN (Pain at the injection site) and ARTHRALGIA (Achy knee issue) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 16-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Jul-2021, the patient experienced VACCINATION SITE PAIN (Pain at the injection site) and ARTHRALGIA (Achy knee issue). On 26-Jul-2021, the patient experienced PRURITUS (Intermittent itching palms,bilateral itching palms,intermittent itching knuckles). The patient was treated with PARACETAMOL (OTC VOLTAREN) for Adverse event, at an unspecified dose and frequency. On 20-Jul-2021, VACCINATION SITE PAIN (Pain at the injection site) had resolved. At the time of the report, PRURITUS (Intermittent itching palms,bilateral itching palms,intermittent itching knuckles) and ARTHRALGIA (Achy knee issue) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. The patient did not experience the same issues after receiving the second dose than compared to the first dose.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: follow up contains added dose details and updated action taken of suspect vaccine and added event of aching in knees, updated outcome of itching both hands, treatment drug added
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Product dose omission issue
Clinical narrative: Real bad headache/"Head is killing me"/feels like head is about to explode/Headache/"Head a lot about it"/; 2nd dose not yet received; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Real bad headache/"Head is killing me"/feels like head is about to explode/Headache/"Head a lot about it"/) and PRODUCT DOSE OMISSION ISSUE (2nd dose not yet received) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Cholesterol.    On 03-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Real bad headache/"Head is killing me"/feels like head is about to explode/Headache/"Head a lot about it"/) and PRODUCT DOSE OMISSION ISSUE (2nd dose not yet received). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at an unspecified dose and frequency. At the time of the report, HEADACHE (Real bad headache/"Head is killing me"/feels like head is about to explode/Headache/"Head a lot about it"/) had not resolved and PRODUCT DOSE OMISSION ISSUE (2nd dose not yet received) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was withdrawn on an unknown date.       no concomitant medication provided.  Patient stated that he took blood pressure and cholesterol medications   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: Non Significant Information available
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Ageusia, Anosmia, Chills, Cough
Clinical narrative: runny nose; loss of taste; loss of smell; abdominal pain; vomiting; muscle ache; nausea; headache; chills; cough; Positive for Covid-19; diarrhea; nasal congestion; This spontaneous case was reported by an other health care professional and describes the occurrence of SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion) and RHINORRHOEA (runny nose) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.  Concurrent medical conditions included Obesity (most recent BMI:32) since 2019 and Hashimoto's disease (Elevated TPO antibodies).    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Positive for Covid-19). On an unknown date, the patient experienced COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills). an unknown date, the patient experienced VOMITING (vomiting). The patient was treated with IVERMECTIN (oral) from 21-Jan-2021 to 23-Jan-2021 at a dose of 3 mg 3 days; VITAMIN D3 (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 1500 IU once a day; VITAMIN C [ASCORBIC ACID] (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 2000 mg once a day and ACETYLSALICYLIC ACID (ASPIRINE) (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 325 mg. At the time of the report, SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), VOMITING (vomiting), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills) outcome was unknown and DIARRHOEA (diarrhea) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Jan-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), VOMITING (vomiting), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills) to be not applicable.    Concomitant product information was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: Follow-up received contain significant information treatment drugs, medical history, lab tests updated.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Headache, Myalgia, Nasal congestion, Nausea
Clinical narrative: runny nose; loss of taste; loss of smell; abdominal pain; vomiting; muscle ache; nausea; headache; chills; cough; Positive for Covid-19; diarrhea; nasal congestion; This spontaneous case was reported by an other health care professional and describes the occurrence of SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion) and RHINORRHOEA (runny nose) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.  Concurrent medical conditions included Obesity (most recent BMI:32) since 2019 and Hashimoto's disease (Elevated TPO antibodies).    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Positive for Covid-19). On an unknown date, the patient experienced COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills). an unknown date, the patient experienced VOMITING (vomiting). The patient was treated with IVERMECTIN (oral) from 21-Jan-2021 to 23-Jan-2021 at a dose of 3 mg 3 days; VITAMIN D3 (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 1500 IU once a day; VITAMIN C [ASCORBIC ACID] (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 2000 mg once a day and ACETYLSALICYLIC ACID (ASPIRINE) (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 325 mg. At the time of the report, SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), VOMITING (vomiting), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills) outcome was unknown and DIARRHOEA (diarrhea) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Jan-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), VOMITING (vomiting), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills) to be not applicable.    Concomitant product information was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: Follow-up received contain significant information treatment drugs, medical history, lab tests updated.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea, SARS-CoV-2 test, SARS-CoV-2 test positive, Vomiting
Clinical narrative: runny nose; loss of taste; loss of smell; abdominal pain; vomiting; muscle ache; nausea; headache; chills; cough; Positive for Covid-19; diarrhea; nasal congestion; This spontaneous case was reported by an other health care professional and describes the occurrence of SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion) and RHINORRHOEA (runny nose) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.  Concurrent medical conditions included Obesity (most recent BMI:32) since 2019 and Hashimoto's disease (Elevated TPO antibodies).    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Positive for Covid-19). On an unknown date, the patient experienced COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills). an unknown date, the patient experienced VOMITING (vomiting). The patient was treated with IVERMECTIN (oral) from 21-Jan-2021 to 23-Jan-2021 at a dose of 3 mg 3 days; VITAMIN D3 (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 1500 IU once a day; VITAMIN C [ASCORBIC ACID] (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 2000 mg once a day and ACETYLSALICYLIC ACID (ASPIRINE) (oral) from 21-Jan-2021 to 27-Jan-2021 at a dose of 325 mg. At the time of the report, SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), VOMITING (vomiting), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills) outcome was unknown and DIARRHOEA (diarrhea) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Jan-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered SARS-COV-2 TEST POSITIVE (Positive for Covid-19), COUGH (cough), DIARRHOEA (diarrhea), NASAL CONGESTION (nasal congestion), RHINORRHOEA (runny nose), AGEUSIA (loss of taste), ANOSMIA (loss of smell), ABDOMINAL PAIN (abdominal pain), VOMITING (vomiting), MYALGIA (muscle ache), NAUSEA (nausea), HEADACHE (headache) and CHILLS (chills) to be not applicable.    Concomitant product information was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: Follow-up received contain significant information treatment drugs, medical history, lab tests updated.
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Vomiting
Clinical narrative: throwing up; fevers; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (throwing up), PYREXIA (fevers) and MYALGIA (Body aches) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VOMITING (throwing up), PYREXIA (fevers) and MYALGIA (Body aches). At the time of the report, VOMITING (throwing up), PYREXIA (fevers) and MYALGIA (Body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided. It was reported that the symptoms occurred 10 days later after the shot.  No treatment information was provided.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Contusion, Petechiae
Clinical narrative: non traumatic painless bruise on the right foot; Petechial rash and bruising; This spontaneous case was reported by a consumer and describes the occurrence of PETECHIAE (Petechial rash and bruising) and CONTUSION (non traumatic painless bruise on the right foot) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     Concurrent medical conditions included Sulfonamide allergy (allergy to sulfa), IgA deficiency since 2020, GERD and Hyperlipidemia. Concomitant products included ATORVASTATIN for High cholesterol.   On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced PETECHIAE (Petechial rash and bruising). On 03-May-2021, the patient experienced CONTUSION (non traumatic painless bruise on the right foot). At the time of the report, PETECHIAE (Petechial rash and bruising) and CONTUSION (non traumatic painless bruise on the right foot) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Pilosoc at a dose of 20 mg used for treatment of GRED and administered via oral route of administration.   This case was linked to MOD-2021-049489 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 13-Aug-2021: Follow up received and patient initial updated. On 17-Aug-2021: Significant follow-up received on 17-AUG-2021 including added new reporter HCP, updated patient's allergic condition , concomitant medication were added, both the events onset date and outcome were updated
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Antibody test, Asthenia, Fatigue, Somnolence
Clinical narrative: Slept for the rest of the afternoon/deep sleep; Weakness; Was so exhausted; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (Slept for the rest of the afternoon/deep sleep), ASTHENIA (Weakness) and FATIGUE (Was so exhausted) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     The patient's past medical history included Clostridium difficile infection (Resistant to antibiotics). Concurrent medical conditions included Allergy NOS since 1954, Asthma since 1954, Atrial fibrillation since 2018, Hyperthyroidism since 1984, Psoriasis since 1990, Autoimmune disorder NOS (Autoimmune conditions) and Cirrhosis liver. Concomitant products included LEVOTHYROXINE, MELATONIN, ZINC, COLECALCIFEROL (VIT D3), FLECAINIDE, APIXABAN (ELIQUIS), DILTIAZEM, LEVOTHYROXINE SODIUM (SYNTHROID) and VITAMIN B+C [ASCORBIC ACID;BIOTIN;CALCIUM CARBONATE;CYANOCOBALAMIN;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RIBOFLAVIN SODIUM PHOSPHATE;THIAMINE HYDROCHLORIDE] for an unknown indication.    On 10-Mar-2021 at 9:45 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced SOMNOLENCE (Slept for the rest of the afternoon/deep sleep) and FATIGUE (Was so exhausted). 10-Mar-2021, the patient experienced ASTHENIA (Weakness). At the time of the report, SOMNOLENCE (Slept for the rest of the afternoon/deep sleep), ASTHENIA (Weakness) and FATIGUE (Was so exhausted) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Jul-2021, Antibody test: 80 (abnormal) The antibody titer was reported as 80.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Treatment information was not provided.  Patient was wondering if she had a cytokine storm based on her antibody titer results and whether she could take the booster dose.   Most recent FOLLOW-UP information incorporated above includes: On 18-Aug-2021: The patients medical history was reported. On 20-Aug-2021: Updated patient's demographics, medical history information, concomitant medications and added an event asthenia.
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Rheumatoid arthritis
Clinical narrative: Attack of Rheumatoid Arthritis; Patient received second dose 6 months after first one; This spontaneous case was reported by a consumer and describes the occurrence of RHEUMATOID ARTHRITIS (Attack of Rheumatoid Arthritis) in a 95-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 052E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Macular degeneration.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jun-2021, the patient experienced RHEUMATOID ARTHRITIS (Attack of Rheumatoid Arthritis) (seriousness criteria hospitalization and medically significant). On 04-Aug-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose 6 months after first one). The patient was hospitalized from 01-Jun-2021 to 04-Jun-2021 due to RHEUMATOID ARTHRITIS. The patient was treated with CORTISONE for Rheumatoid arthritis, at an unspecified dose and frequency. On 04-Jun-2021, RHEUMATOID ARTHRITIS (Attack of Rheumatoid Arthritis) outcome was unknown. On 04-Aug-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose 6 months after first one) had resolved.            No concomitant medications were reported. The patient took Tylenol before the shot and used CBD oil on her arm 2-3 days after the shot.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 18-Aug-2021: follow up received and it includes second dose details On 31-Aug-2021: Significant follow-up appended - serious event added; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, Product temperature excursion issue
Clinical narrative: doses were administered from one expired vial; vial was moved from the freezer to the refrigerator on 09Jul2021 and puntured on 11Jun 2021; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses were administered from one expired vial) and PRODUCT TEMPERATURE EXCURSION ISSUE (vial was moved from the freezer to the refrigerator on 09Jul2021 and puntured on 11Jun 2021) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jul-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (vial was moved from the freezer to the refrigerator on 09Jul2021 and puntured on 11Jun 2021). On 09-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses were administered from one expired vial). At the time of the report, EXPIRED PRODUCT ADMINISTERED (doses were administered from one expired vial) and PRODUCT TEMPERATURE EXCURSION ISSUE (vial was moved from the freezer to the refrigerator on 09Jul2021 and puntured on 11Jun 2021) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant use were reported No treatment medication were reported.  A public health assistant called-in on 09 Aug2021 to report five doses were administered from one expired vial. The vials lot number was 041B21A. The vial was moved from the freezer to the refrigerator on 09Jul2021. The vials was first punctured on 11 Jul2 021. The vial was left in the refrigerator and on 08Aug2021 five patients were given doses from the expired vial. The caller confirmed the vial never went through any temperature excursions.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received a dose from a vial after 14 hours since it was punctured for the first time; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received a dose from a vial after 14 hours since it was punctured for the first time) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048B21A) for COVID-19 vaccination.     Medical history was not provided by the reporter.     On 06-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received a dose from a vial after 14 hours since it was punctured for the first time). On 06-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Received a dose from a vial after 14 hours since it was punctured for the first time) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No treatment information was provided.  Date the vial was initially stored in the refrigerator was 06 Aug 2021.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: received first dose moderna june 26,and never received second dose yet; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (received first dose moderna june 26,and never received second dose yet) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (received first dose moderna june 26,and never received second dose yet). At the time of the report, PRODUCT DOSE OMISSION ISSUE (received first dose moderna june 26,and never received second dose yet) had resolved.            Concomitant product information was not provided. Treatment information was not provided.   Reporter did not allow further contact